Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Glucose, Magnesium chloride hexahydrate, Potassium chloride, Sodium acetate trihydrate, Sodium chloride, Sodium gluconate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for 2. What you need to know before you are given Plasma-Lyte & Glucose Infusion 3. How you will be given Plasma-Lyte & Glucose Infusion 4. Possible side effects 5. How to store Plasma-Lyte & Glucose Infusion 6. Contents of the pack and other information
Plasma-Lyte & Glucose Infusion
1. What Plasma-Lyte & Glucose Infusion is and what it is used for
Do NOT receive Plasma-Lyte & Glucose Infusion if you are suffering from any of the following conditions
Pharmacotherapeutic group: "Electrolytes with Carbohydrates" – ATC code: "B05BB02" Plasma-Lyte & Glucose Infusion is a solution of the following substances in water:
(metabolic or respiratory alkalosis)
Warnings and precautions Plasma-Lyte & Glucose Infusion is a hyper-osmotic (concentrated) solution. Your doctor will take this into account when calculating how much solution to give you. Please tell your doctor if you have or have had any of the following medical conditions:
Children Plasma-Lyte & Glucose Infusion should be given with special care in children. Newborns, especially those born premature and with low birth weight, are at increased risk of developing low or high levels of sugar in the blood (hypo or hyperglycemia), which may lead to complications.
Other medicines and Plasma-Lyte & Glucose Infusion Tell your doctor or nurse if you are taking or have recently taken or might take any other medicines. The following medicines must not be used while you are receiving an infusion of Plasma-Lyte & Glucose Infusion:
(these medicines may be included in combination medicinal products. See also "You must NOT receive Plasma-Lyte & Glucose Infusion if you are suffering from any of the following conditions" at the start of this section). The use of the following medicines is not recommended while you are receiving an infusion of Plasma-Lyte & Glucose Infusion:
Plasma-Lyte & Glucose Infusion will usually be given to you through a plastic tube attached to a needle in a vein. However, your doctor may use another method to give you the medicine. Any unused solution should be thrown away. You should NOT be given an infusion of Plasma-Lyte & Glucose Infusion from a bag that has been partly used.
If you receive more Plasma-Lyte & Glucose Infusion than you should
Plasma-Lyte & Glucose Infusion with food and drink You should ask your doctor about what you can eat or drink.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine. You may receive Plasma-Lyte & Glucose Infusion if you are pregnant or breast-feeding. Your doctor will monitor the levels of chemicals in your blood and the amount of fluid in your body. However, if another medicine is to be added to your solution for infusion during pregnancy or breast-feeding you should:
Driving and using machines Ask your doctor or pharmacist for advice before driving or using machines.
Plasma-Lyte & Glucose Infusion You will be given Plasma-Lyte & Glucose Infusion by a doctor or nurse. Your doctor will decide how much you need and when it is to be administered. This will depend on your age, weight, condition and the reason for treatment. The amount you are given may also be affected by other treatments you are receiving. You should NOT be given Plasma-Lyte & Glucose Infusion if there are particles floating in the solution or if the pack is damaged in any way. 4
If you are given too much Plasma-Lyte & Glucose Infusion (over-infusion) or it is given too fast, this may lead to the following symptoms:
causes pain, swelling or redness in the area of the clot
directly via (see details below). By This can cause redness, pain or burning reporting side effects, you can help provide more and swelling along the path of the vein into information on the safety of this medicine. which the solution is infused.
polyolefin/polyamide plastic bags (Viaflo). Each bag is wrapped in a sealed, protective, outer plastic overpouch. The bag sizes are:
Ireland HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie E-mail: [email protected] UK Yellow Card Scheme Tel: Freephone 0808 100 3352 www.mhra.gov.uk/yellowcard
Malta ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturers
Plasma-Lyte & Glucose Infusion
Marketing Authorisation Holder:
Keep this medicine out of the sight and reach of children. Do not store above 30oC. You should not be given this medicine after the expiry date which is stated on the bag after EXP. The expiry date refers to the last day of that month. You should not be given this medicine if you notice particles floating in the solution or if the unit is damaged in any way.
United Kingdom Baxter Healthcare Ltd Caxton Way, Thetford, Norfolk, IP24 3SE United Kingdom Ireland and Malta Baxter Holding B.V. Kobaltweg 49, 3542CE Utrecht, Netherlands Manufacturers in Great Britain: Manufacturers In Ireland:
What Plasma-Lyte & Glucose Infusion contains The active substances are:
Baxter SA Boulevard René Branquart, 80 7860 Lessines Belgium
Baxter SA Boulevard René Branquart, 80 7860 Lessines Belgium
Baxter Healthcare Ltd. Caxton Way, Thetford Norfolk IP24 3SE United Kingdom
Bieffe Medital Sabiñanigo Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
Bieffe Medital Sabiñanigo Ctra de Biescas, Senegüé 22666 Sabiñanigo (Huesca) Spain
This leaflet was last revised in Dec 2025 For information about Plasma-Lyte & Glucose or to request this leaflet in formats such as audio or large print please contact the Marketing Authorisation Holder: Tel: + 44(0)1635 206345.
What Plasma-Lyte & Glucose Infusion looks like and contents of the pack Plasma-Lyte & Glucose Infusion is a clear solution, free from visible particles. It is supplied in 6
Baxter, Plasma-Lyte and Viaflo are trademarks of Baxter International lnc. TH-30-02-270
Plasma-Lyte 148 & Glucose 5% w/v Solution for Infusion The following information is intended for healthcare professionals only: Handling and Preparation
The solution is for intravenous administration through sterile administration set using aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system. The solution should be inspected visually for Additives may be introduced before infusion or during particulate matter and discolouration prior to infusion through the re-sealable medication port. administration whenever solution and container Adding other medications or using an incorrect permit. Do not administer unless the solution is administration technique might cause the clear and the seal is intact. Do not remove unit appearance of fever reactions due to the possible from overwrap until ready for use. introduction of pyrogens. In case of an adverse The inner bag maintains the sterility of the product. reaction, infusion must be stopped immediately. Administer immediately following the insertion of Discard after single use. infusion set. Discard any unused portion. In order to avoid potentially fatal over infusion of Do not reconnect partially used bags. intravenous fluids to the neonate, special attention 1. Opening needs to be paid to the method of administration. a. Remove the Viaflo container from the When using a syringe pump to administer overpouch just before use. intravenous fluids or medicines to neonates, a bag b. Check for minute leaks by squeezing inner of fluid should not be left connected to the syringe. bag firmly. If leaks are found, discard When using an infusion pump all clamps on the solution, as sterility may be broken. intravenous administration set must be closed c. Check the solution for clarity and absence before removing the administration set from the of foreign matter. If solution is not clear or pump, or switching the pump off. This is required contains foreign matter, discard the solution. regardless of whether the administration set has 2. Preparation for administration an anti-free flow device. The intravenous infusion The solution should NOT be administered through a device and administration equipment must be peripheral vein. frequently monitored. Use sterile material for preparation and Do not use plastic containers in series connections. Such use could result in air embolism administration. a. Suspend container from eyelet support. due to residual air being drawn from the primary b. Remove plastic protector from outlet port at container before the administration of the fluid bottom of container: from the secondary container is completed.
TH-30-02-270
3. Techniques for injection of additive medications
5. Incompatibilities of additive medications
Warning: Additives may be incompatible Check additive compatibility with both the solution and container prior to use. When additive is used, verify osmolarity prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored. (see Paragraph 5 "Incompatibilities of additive medications" below).
When introducing additives to Plasma-Lyte & Glucose Infusion, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives. Incompatibility of the medicinal product to be added with the solution in Viaflo container must be assessed before addition. The Instructions for Use of the medicinal product to be added must be consulted.
To add medication before administration a. Disinfect medication port. b. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. c. Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix. Caution: Do not store bags containing added medications. To add medication during administration a. Close clamp on the set. b. Disinfect medication port. c. Using syringe with 19 gauge (1.10 mm) to 22 gauge (0.70 mm) needle, puncture re-sealable medication port and inject. d. Remove container from IV pole and/or turn to an upright position. e. Evacuate both ports by tapping gently while the container is in an upright position. f. Mix solution and medication thoroughly. g. Return container to in use position, re-open the clamp and continue administration.
Before adding a substance or medication, verify it is soluble and/or stable in water and that the pH range of Plasma-Lyte & Glucose Infusion is appropriate (pH 4.0 – 6.0). After addition, check for a possible colour change and/or the appearance of precipitates, insoluble complexes or crystals. Glucose 5% solutions are not compatible with blood or red blood cells, as haemolysis and clumping have been described. Those additives known to be incompatible should not be used.
4. In-use shelf-life: Additives Chemical and physical stability of any additive at the pH of Plasma-Lyte & Glucose Infusion in the Viaflo container should be established prior to use. From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless reconstitution has taken place in controlled and validated aseptic conditions.
Baxter, Plasma-Lyte and Viaflo are trademarks of Baxter International lnc.
8
TH-30-02-270
Plasma-Lyte 148 & Glucose 5% w/v solution for infusion comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Plasma-Lyte 148 & Glucose 5% w/v solution for infusion is glucose, magnesium chloride hexahydrate, potassium chloride, sodium acetate trihydrate, sodium chloride, sodium gluconate.
This leaflet reproduces the patient information leaflet approved for Plasma-Lyte 148 & Glucose 5% w/v solution for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Plasma-Lyte 148 & Glucose 5% w/v is indicated:
- for fluid replacement with carbohydrate supply (e.g. after burns, head injury, fracture, infection, and peritoneal irritation),
- as intraoperative fluid replacement,
- in mild to moderate metabolic acidosis, also in case of lactate metabolism impairment.
Adults, the Elderly, Adolescents and Children:
The dosage and rate of administration depend on the age, weight, clinical and biological conditions of the patient and concomitant therapy.
Fluid balance, blood glucose, and serum electrolytes should be monitored before and during administration (see sections 4.4, 4.5, 4.6 and 4.8).
Recommended dosage:
The recommended dosage is:
- for adults, the elderly and adolescents: 500 ml to 3 litres / 24h
- for infants, toddlers and children:
- 0-10 kg body weight : 100 ml/kg/24h
- 10-20 kg body weight : 1000 ml + (50 ml /kg over 10 kg) /24h
- > 20 kg body weight : 1500 ml + (20 ml/kg over 20 kg)/24h
Administration rate:The infusion rate is usually 40 mL/kg/24h in adults, the elderly and adolescents.
When used for intraoperative fluid replacement, normal rate can be higher and is about 15 mL/kg/h.
In paediatric patients the infusion rate is 5 ml/kg/h in average but the value varies with age: 6-8 mL/kg/h for infants, 4-6 mL/kg/h for toddlers, and 2-4 mL/kg/h for children.
The infusion rate should not exceed the patient's glucose oxidation capacities in order to avoid hyperglycaemia. Therefore the maximum acute administration rate ranges from 5mg/kg/min for adults to 10-18 mg/kg/min for babies and children, depending on the age and the total body mass.
Note:
- infants and toddlers: aged from 28 days to 23 months (a toddler is an infant who can walk)
- Children: aged from 2 to 11 years.
Use in Paediatric Patients
Safety and effectiveness of Plasma-Lyte 148 & Glucose 5% w/v solution in children have not been established by adequate and well controlled trials.
Use in Geriatric Patients
When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.
Method of administration:
The administration is performed by intravenous route.
The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system.
Glucose solutions should NOT be administered through the same infusion equipment as whole blood, as hemolysis and clumping can occur.
Due to its hyper-osmolality, this solution should NOT be administered through a peripheral vein.
The solution should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless the solution is clear and the seal is intact.
Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the solution. Administer immediately following the insertion of infusion set.
Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Additives may be introduced before infusion or during infusion through the injection site.
The solution is contra-indicated in patients presenting:
- Hyperkalaemia
- Renal failure
- Heart block
- Metabolic or respiratory alkalosis
- Hypochlorhydria
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
The solution is also contraindicated in case of uncompensated diabetes, other known glucose intolerances (such as metabolic stress situations), hyperosmolar coma, hyperglycaemia, hyperlactataemia
Electrolyte balance
Plasma-Lyte 148 & Glucose 5% w/v solution is not indicated for the treatment of hypochloraemic hypokalaemic alkalosis.
Plasma-Lyte 148 & Glucose 5% w/v solution is not indicated for the primary treatment of severe metabolic acidosis neither for the treatment of hypomagnesemia.
Hyponatraemia:
Treatment with intravenous fluids having a lower sodium concentration than the patient's serum sodium may cause hyponatremia (see section 4.2). Children, patients with reduced cerebral compliance, patients with non-osmotic vasopressin release (e.g. in acute illness, trauma, post-operative stress, central nervous system diseases), and patients exposed to vasopressin agonists and other drugs that can lower serum sodium (see section 4.5) are at particular risk of acute hyponatraemia. Acute hyponatraemia can lead to acute brain oedema and life-threatening brain injury.
Use in Patients with or at Risk for and from Hypermagnesemia
Parenteral magnesium salts should be used with caution in less severe degrees of renal impairment and in patients with myasthenia gravis. Patients should be monitored for clinical signs of excess magnesium, particularly when being treated for eclampsia (see also Section 4.5 - Interaction with other medicinal products and other forms of interaction).
Use in patients with Hypocalcaemia
Plasma-Lyte 148 & Glucose 5% w/v solution contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not protein-bound) calcium. Plasma-Lyte 148 & Glucose 5% w/v solution should be administered with particular caution to patients with hypocalcaemia.
Use in Patients with or at Risk for Hyperkalemia
Solutions containing potassium salts should be administered with caution to patients with cardiac disease or conditions predisposing to hyperkalaemia such as renal or adrenocortical insufficiency, acute dehydration, or extensive tissue destruction as occurs with severe burns (see also Section 4.5). The plasma potassium level of the patient should be particularly closely monitored in patients at risk of hyperkalaemia.
The following combinations are not recommended; they increase the concentration of potassium in the plasma and may lead to potentially fatal hyperkalaemia notably in case of renal failure increasing the hyperkalaemic effects (see 4.5):
• .Concomitant use with potassium-sparing diuretics (amiloride, potassium canreonate, spironolactone, triamterene)
• Angiotensin converting enzyme inhibitors (ACEi) and, by extrapolation, angiotensin II receptor antagonists : hyperkalaemia potentially lethal
• Tacrolimus, cyclosporine
Use in patients with potassium deficiency
Although Plasma-Lyte 148 & Glucose 5% w/v solution has a potassium concentration similar to the concentration in plasma, it is insufficient to produce a useful effect in case of severe potassium deficiency and therefore it should not be used for this purpose.
Fluid balance/renal function
Risk of Fluid and/or Solute Overload and Electrolyte Disturbances
The patient's clinical status and laboratory parameters (fluid balance, blood and urine electrolytes as well as acid-base balance) must be monitored during use of this solution.
Depending on the volume and rate of infusion, intravenous administration of Plasma-Lyte 148 & Glucose 5% w/v solution can cause
− fluid and/or solute overload resulting in overhydration/hypervolemia therefore high volume infusion must be used under specific monitoring in patients with cardiac, pulmonary or renal failure.
Use in Patients with Hypervolaemia or Overhydration, or Conditions that Cause Sodium Retention and Oedema
Plasma-Lyte 148 & Glucose 5% w/v solution should be administered with particular caution to hypervolaemic or overhydrated patients.
Solutions containing sodium chloride should be carefully administered to patients with hypertension, heart failure, peripheral or pulmonary edema, impaired renal function, pre-eclampsia, aldosteronism, or other conditions associated with sodium retention (see also Section 4.5 - Interaction with other medicinal products and other forms of interaction).
Use in Patients with Severe Renal Impairment
Plasma-Lyte 148 & Glucose 5% w/v solution should be administered with particular caution to patients with severe renal impairment. In such patients administration of Plasma-Lyte 148 & Glucose 5% w/v solution may result in sodium and/or potassium or magnesium retention.
Acid-base balance
Use in Patients with or at Risk for Alkalosis
Plasma-Lyte 148 & Glucose 5% w/v solution should be administered with particular caution to patients with alkalosis or at risk for alkalosis. Excess administration of Plasma-Lyte 148 & Glucose 5% w/v solution can result in metabolic alkalosis because of the presence of acetate and gluconate ions.
Other warnings
Hypersensitivity Reactions
Hypersensitivity/infusion reactions, including anaphylactoid reactions, have been reported with Plasma-Lyte 148 & Glucose 5% w/v solution.
The infusion must be stopped immediately if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Solutions containing glucose should be used with caution in patients with known allergy to corn or corn products.
Administration
Administration in the postoperative period shortly after recovery from neuromuscular block should be used with caution since magnesium salts can lead to recurarisation effect.
Administration of glucose containing solutions may lead to hyperglycaemia. In this case, it is recommended not to use this solution after acute ischaemic strokes as hyperglycaemia has been implicated in increasing cerebral ischaemic brain damage and impairing recovery. During long term parenteral treatment, a convenient nutritive supply must be given to the patient, electrolyte supply should be taken into account and adjusted accordingly.
Use in patients with diabetes
If administered to diabetics or patients with renal insufficiency, close monitoring of glucose levels is required, and insulin and/or potassium requirements may be modified.
Use in Patients with or at Risk for Hyperglycaemia
Solutions containing glucose should be used with caution in patients with impaired glucose tolerance or diabetes mellitus.
Because Plasma-Lyte 148 & Glucose 5% w/v solution contains glucose as well as gluconate (a portion of which may be metabolized to glucose), administration of Plasma-Lyte 148 & Glucose 5% w/v solution that exceeds the metabolic capacity for glucose may lead to hyperglycaemia.
In order to avoid hyperglycaemia the infusion rate should not exceed the patient's ability to utilise glucose.
Due to glucose presence, Plasma-Lyte 148 & Glucose 5% w/v should not be infused concomitantly to massive blood transfusion (risk of pseudo-agglutination).
Administration of glucose containing solutions may lead to hyperglycaemia. In this case, it is recommended not to use this solution after acute ischaemic strokes as hyperglycaemia has been implicated in increasing cerebral ischaemic brain damage and impairing recovery.
Early hyperglycemia has been associated with poor outcomes in patients with severe traumatic brain injury.
Glucose-containing solutions should, therefore, be used with caution in patients with head injury, in particular during the first 24 hours following the trauma.
Newborns – especially those born premature and with low birth weight -(Please refer below section - Paediatric population)
If hyperglycaemia occurs, the rate of glucose administration should be reduced and/or insulin administered, or the insulin dose adjusted.
Paediatric population
Newborns – especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitits, bronchopulmonary dysplasia, prolonged length of hospital stay, and death.
The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in paediatric intravenous fluid therapy.
In order to avoid potentially fatal over infusion of intravenous fluids to the neonate, special attention needs to be paid to the method of administration. When using a syringe pump to administer intravenous fluids or medicines to neonates, a bag of fluid should not be left connected to the syringe. When using an infusion pump all clamps on the intravenous administration set must be closed before removing the administration set from the pump, or switching the pump off. This is required regardless of whether the administration set has an anti-free flow device. The intravenous infusion device and administration equipment must be frequently monitored.
Plasma electrolyte concentrations should be closely monitored in the paediatric population as this population may have impaired ability to regulate fluids and electrolytes.
Osmolarity
Plasma-Lyte 148 & Glucose 5% w/v solution is a hyper-osmotic solution, having an osmolarity of 572 mOsmol/L. The normal physiologic serum osmolarity range is approximately 280 to 310 mOsmol/L.
Administration of hyper-osmotic solutions may cause venous irritation, including phlebitis.
Hyperosmolar solutions should be administered with caution to patients with hyperosmolar states.
Interference with laboratory tests for gluconate containing solutions
There have been reports of false-positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving Baxter gluconate containing Plasmalyte solutions. These patients were subsequently found to be free of Aspergillus infection. Therefore, positive test results for this test in patients receiving Baxter gluconate containing Plasmalyte solutions should be interpreted cautiously and confirmed by other diagnostic methods.
Administration
Adding other medications or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. In case of an adverse reaction, infusion must be stopped immediately.
For information on incompatibilities and preparation of the product and additives, please see section 6.2 and 6.6.
Hyperglycaemic effect of this solution could modify the insulin needs of diabetic patients.
Drugs that can increase the risk for hyponatremia Drugs that can lower serum sodium may increase the risk of acquired hyponatraemia following treatment with intravenous fluids inappropriately balanced to the need of the patient in terms of fluid volume and sodium content (see sections 4.2, 4.4, 4.6 and 4.8). Examples are diuretics, non-steroid anti-inflammatory drugs (NSAIDs), antipsychotics, selective serotonin reuptake inhibitors, opioids, antiepileptics, oxytocin, and chemotherapy.
Interaction related to the presence of sodium:
- Corticoids/Steroids and carbenoxolone, which are associated with the retention of sodium and water (with oedema and hypertension).
Interaction related to the presence of potassium:
The following combinations increase the concentration of potassium in the plasma and may lead to potentially fatal hyperkalaemia notably in case of renal failure increasing the hyperkalaemic effects:
Combination not recommended
- Potassium-sparing diuretics (amiloride, potassium canreonate, spironolactone, triamterene, alone or in combination) (see 4.4),
- Angiotensin converting enzyme inhibitors (ACEi) and, by extrapolation, angiotensin II receptor antagonists: hyperkalaemia potentially lethal (see 4.4),
- Tacrolimus, cyclosporin (see 4.4)
Administration of potassium in patients treated with such medications can produce severe and potentially fatal hyperkalaemia, particularly in patients with severe renal insufficiency.
Interaction related to the presence of magnesium:
- Neuromuscular blockers such as tubocurarine, suxamethonium, and vecuronium whose effects are enhanced by the presence of magnesium.
- Acetylcholine whose release and effects are reduced by magnesium salts what may contribute to neuromuscular blockade.
- Aminoglycoside antibacterials and nifedipine that have additive effects with parenteral magnesium and enhanced the neuromuscular blocking.
Interaction related to the presence of acetate and gluconate (which are metabolised into bicarbonate):
- Caution is advised when administering Plasma-Lyte 148 & Glucose 5% w/v solution to patients treated with drugs for which renal elimination is pH dependent. Due to its alkalinizing effect (formation of bicarbonate), Plasma-Lyte 148 & Glucose 5% w/v solution may interfere with the elimination of such drugs.
- Renal clearance of acidic drugs such as salicylates, barbiturates and lithium may be increased because of the alkalinisation of urine by the bicarbonate resulting from acetate and gluconate metabolism.
- Renal clearance of alkaline drugs, such as sympathomimetics (e.g. ephedrine, pseudoephedrine) and stimulants (e.g. dexamphetamine sulphate, phenfluramine hydrochloride) may be decreased.
There are no adequate data from the use of Plasma-Lyte 148 & Glucose 5% w/v solution in pregnant or lactating women. The potential risks and benefits for each specific patient should be carefully considered before using Plasma-Lyte 148 & Glucose 5% w/v solution in pregnancy or lactating woman.
If Plasma-Lyte 148 & Glucose 5% w/v solution is administrated to pregnant women during labour, particularly if administered in combination with oxytocin, there may be an increased risk for hyponatraemia (see section 4.4, 4.5 and 4.8).
There is no information of the effects of Plasma-Lyte 148 & Glucose 5% w/v solution on the ability to drive and use machines.
The following adverse reactions have been reported in the postmarketing experience, with unspecified Plasma-lyte products and Plasma-lyte products with Glucose, listed by MedDRA System Organ Class (SOC), then by Preferred Term in order of severity, where feasible.
Frequency is defined as very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100): rare (≥ 1/10000 to < 1/1000); very rare (< 1/10 000); and not known (cannot be estimated from the available data).
System Organ Class (SOC)
MedDRA Preferred Term
Frequency
Immune system disorders
Hypersensitivity /infusion reaction (including Anaphylactoid reaction, and the following manifestations:
Hypotension,
Chest discomfort,
Dyspnea,
Wheezing,
Flushing,
Hyperaemia,
Asthenia,
Urticaria,
Cold sweat,
Pyrexia,
Chills
*Tachycardia, Palpitations, Chest pain, Respiratory rate increased, Feeling abnormal, Piloerection, Oedema Peripheral)
Not known
Metabolism and nutrition disorders
Hyperkalaemia, Hyperglycaemia
Hypervolemia
Hyponatraemia
Not known
Not known
Nervous system disorders
Seizures
Hyponatraemic encephalopathy
Not known
Vascular disorders
Thrombophlebitis
Venous thrombosis
Not known
Not known
Skin and subcutaneous tissue disorders
Urticaria
Not known
General disorders and administration site conditions
Infusion site reactions
(e.g., Burning sensation
Fever
Injection site pain
Injection site reaction
Injection site phlebitis
Injection site irritation
Injection site infection
Extravasation)
Not known
Investigations
False positive laboratory results (Bio-Rad Laboratories' Platelia Aspergillus EIA test) (see Section 4.4)
Not known
* The adverse reactions highlighted in italic are reported for other similar products
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: [email protected].
Excessive administration of a glucose-containing solution may lead to hyperglycemia, hyperosmolarity, osmotic diuresis, and dehydration.
Overuse or too fast administration may lead to water and sodium overload with a risk of oedema, particularly when there is a defective renal sodium excretion. In this case extra renal dialysis may be necessary.
Excessive administration of potassium may lead to the development of hyperkalemia, especially in patients with renal impairment. Symptoms include paresthesia of the extremities, muscle weakness, paralysis, cardiac arrhythmias, heart block, cardiac arrest, and mental confusion. Treatment of hyperkalemia involves the administration of calcium, insulin (with glucose) sodium bicarbonate, exchange resins or dialysis.
Excessive parenteral administration of magnesium salts leads to the developments of hypermagnesemia, important signs of which are loss of deep tendon reflexes and respiratory depression, both due to neuromuscular blockade. Other symptoms of hypermagnesemia may include nausea, vomiting, flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness, bradycardia, coma, and cardiac arrest. A patient with supralethal hypermagnesemia was successfully treated using assisted ventilation, calcium chloride, administered intravenously, and forced diuresis with mannitol infusions.
Excessive administration of chloride salts may cause a loss of bicarbonate with an acidifying effect.
Excessive administration of compounds, such as sodium acetate and sodium gluconate, which are metabolized to form the bicarbonate anion may lead to hypokalemia and metabolic alkalosis, especially in patients with impaired renal function. Symptoms may include mood changes, tiredness, shortness of breath, muscle weakness, and irregular heartbeat. Muscle hypertonicity, twitching, and tetany may develop especially in hypocalcemic patients. Treatment of metabolic alkalosis associated with bicarbonate overdose consists mainly of appropriate correction of fluid and electrolyte balance.
Prolonged administration or rapid infusion of large volumes of glucose containing solutions may lead to hyperosmolarity, dehydration, hyperglycaemia, hyperglucosuria and osmotic diuresis (due to hyperglycaemia).
When overdose is related to medications added to the solution infused, the signs and symptoms of over infusion will be related to the nature of the additive being used. In the event of accidental over infusion, treatment should be discontinued and the patient should be observed for the appropriate signs and symptoms related to the drug administered. The relevant symptomatic and supportive measures should be provided as necessary.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Glucose, Magnesium chloride hexahydrate, Potassium chloride, Sodium acetate trihydrate, Sodium chloride, Sodium gluconate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Glucose, Magnesium chloride hexahydrate, Potassium chloride, Sodium acetate trihydrate, Sodium chloride, Sodium gluconate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Plasma-Lyte 148 & Glucose 5% w/v solution for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.